Oxbridge desktop technology aims to disrupt gene editing field
Oxford Genetics and Cambridge partner Sphere Fluidics have launched a multi-partner collaboration to expedite the development of automated microfluidic systems for rapid and high-throughput gene editing in mammalian cell lines.
Sphere Fluidics will act as the lead partner, looking to utilise its extensive expertise in microfluidic systems to produce new products designed to meet the requirements of multiplexed gene editing workflows.
Oxford Genetics and the University of Edinburgh will provide input into industrial and application specific requirements, both in relation to standard engineering approaches but also for more difficult host systems, including stems cells and primary cell lines, and in discovery contexts.
Twist Bioscience will contribute DNA synthesis capabilities and required reagents for the project.
Sphere Fluidics CEO, Frank Craig said: “We are very pleased to join forces with a company of the calibre of Oxford Genetics. They bring excellent expertise in cell biology, gene editing and workflow automation.
“We plan to develop a desktop system that will miniaturise and automate the genome editing of single cells. Such a product is highly innovative and will be disruptive in that sector.
“This system will enable scientists to easily perform automated genome editing and create new cell lines and valuable biomedical products.”